Product Description
Follistatin (FLGR242), is a novel fragmented, modified version of Follistatin-344 (FST-344) that does not bind to the protein activin. Activin is responsible for the negative effects of myostatin inhibition such as unwanted cellular growth in laboratory models. It also contains a patented albumin binder.
Follistatin protein (FST) fused with an albumin-binding construct that uses a hydrophilic glycine-serine linker to achieve high-affinity binding to serum albumin (<20 nM Kd). This recombinant technology allows researchers to study follistatin-albumin interactions and protein trafficking in experimental systems.
Research applications include muscle mass development studies, activin neutralization assays, and TGF-β superfamily pathway modulation with albumin binding dynamics. The construct maintains biological activity while enabling investigation of albumin as a carrier protein.
US GMP-manufactured with third-party verification and comprehensive COAs for reproducible research outcomes.
Peptide Information
| Property | Value |
|---|---|
| Peptide Type | Follistatin-Albumin Binding Construct |
| Technology | Albumin-binding peptide fusion (GGSGGSGGSGGRLIEDICLPRWGCLWEDD linker) |
| Molecular Weight | ~40 kDa |
| Binding Affinity | <20 nM |
| Synonyms | FST-Albumin Construct, Extended Half-Life Follistatin |
Lyophilized Peptides:
These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.
Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug.
